Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$7.88MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shao-Lee Lin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- 2.46
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -29.20
Financials
Revenue
$7.88M+4479.7%Net Income
$-153.07MEBITDA
$-87.69MFree Cash Flow
$-29.00MEPS (diluted)
$-24.14Shares Outstanding (diluted)
6.34M+821.6%Operating Expenses
$95.57MCash & Debt
$17.39MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $27.47M | $-26.60M | $-8.40 |
| 2024 | $9.29M | $-40.67M | $-21.60 |
| 2023 | $5.49M | $-50.73M | $-33.30 |
| 2022 | $1.25M | $-53.01M | $-44.70 |
| 2021 | $14.94M | $-44.16M | $-42.30 |
| 2020 | $3.15M | $-44.78M | $-46.80 |
| 2019 | $3.46M | $-36.70M | $-49.80 |
| 2018 | $1.14M | $-38.98M | $-58.20 |
| 2017 | $0.00 | $-23.23M | $-33.90 |
| 2016 | $0.00 | $-7.66M | $-11.10 |
| 2015 | $0.00 | $-1.93M | $-7.80 |
Valuation
CUEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (5)
- Newsmarketbeat.com·8d ago·Neutral
Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response Cue Biopharma NASDAQ: CUE reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines.
View source ↗ - Newsseekingalpha.com·14d ago·Positive
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA I am initiating Cue Biopharma with a "Buy" rating, driven by positive phase 2 results for CUE-221 in chronic spontaneous urticaria [CSU]. CUE-221's novel dual mechanism of action demonstrated superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution at 12 weeks [p < 0.005]. Upcoming catalysts include 36-week PK and IgE data in 2026, and planned phase 2b/3 global studies in CSU and food a…
View source ↗ - Newsseekingalpha.com·14d ago·Positive
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-2.24 per share
Typical surprise +25.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-24.14 vs $-1.69miss
- Thu, May 14$-1.08 vs $-3.30beat
- Mon, Mar 16$0.30 vs $-2.70beat
- Wed, Nov 12$-2.10 vs $-2.80beat
- Tue, Aug 12$-2.70 vs $-3.90beat
- Mon, May 12$-5.11 vs $-4.20miss
Estimates and results for CUE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CUE officers and directors.
- Bought
- $631k
- Sold
- $2.0m
8 trades
11 trades
- Ray Sumitasold
- Ray Sumitasold
- Ray Sumitasold
- Meluzio Michael Vincentsold
- Meluzio Michael Vincentsold
- Meluzio Michael Vincentsold
- Lin Shao-leesold
- Lin Shao-leesold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CUE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.